Paper Details

  1. Home
  2. Paper Details

AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.

Author:

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

AVP-786, a deuterated (d6)-dextromethorphan/quinidine, is being investigated as a treatment for agitation in Alzheimer's disease. AVP-786 has been granted fast-track designation by the FDA and is currently in a Phase III clinical development program. AVP-923, a similar drug, was shown to be well tolerated and effective in reducing agitation in Alzheimer's disease in a Phase II trial.
Paper Details　
Original Abstract of the Article :
Agitation is common and distressing in patients with Alzheimer-type dementia, but safe, effective treatments remain elusive. Psychological treatments are first-line options, but they have limited efficacy. Off-label psychotropic medications are frequently used, but they also have limited effectivene...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/13543784.2017.1267726

データ提供：米国国立医学図書館（NLM）

AVP-786 for Agitation in Dementia: A Hopeful Oasis in a Foggy Desert

The desert of dementia can be a lonely and confusing place, often characterized by agitation and behavioral disturbances. This study explores the potential of a new drug, AVP-786, to treat agitation in patients with Alzheimer's disease. The authors delve into the drug's development, pharmacokinetic profile, and safety. They use a method similar to navigating a foggy desert to find the best path for treatment. Their findings suggest that AVP-786, a derivative of dextromethorphan, may offer a safe and effective way to reduce agitation in patients with Alzheimer's disease. This is like finding a clear path through the fog, allowing travelers to navigate safely and effectively.

A New Trail in the Foggy Desert of Dementia: AVP-786

The study suggests that AVP-786 may provide a new avenue for treating agitation in patients with Alzheimer's disease. This is like discovering a new trail that leads to a calmer and more peaceful oasis. However, further research is needed to confirm its effectiveness and long-term safety. This is like exploring the new trail further to assess its viability and potential risks.

Navigating the Foggy Desert of Dementia: Seeking Calm and Clarity

This study offers hope for patients and caregivers facing the challenges of Alzheimer's disease. It underscores the importance of ongoing research and development in the search for effective treatments for dementia. This is like having a team of explorers constantly seeking new paths and solutions in the foggy desert of cognitive decline.

Dr.Camel's Conclusion

This study is a reminder that even in the foggy desert of dementia, there is hope for finding clarity and calm. We must continue to explore new pathways and treatments to improve the lives of those affected by this complex and challenging condition.

Date :
  1. Date Completed 2017-03-10
  2. Date Revised 2017-03-10
Further Info :

Pubmed ID

27936965

DOI: Digital Object Identifier

10.1080/13543784.2017.1267726

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.